Intravenous fluid container, single use Australia - English - Department of Health (Therapeutic Goods Administration)

intravenous fluid container, single use

addedpharma - australia/nz - 35127 - intravenous fluid container, single use - these eva bags are sterile single-use consumables that have multiple uses; (1) they can be used as a resevoir to fill up and prepare syringes, bags, and vials, or (2) they can be used as a container of medication such as tpns or antibiotics which can then be administered via gravity infusion. please note that the eva bags do not include any direct connection to the patient.

Syringe, general-purpose Australia - English - Department of Health (Therapeutic Goods Administration)

syringe, general-purpose

addedpharma - australia/nz - 47017 - syringe, general-purpose - in line with gmdn 47017, sterile empty syringe multipacks for general purpose preparation, injection and aspiration of fluids from vials, ampoules and other pharmaceutical reservoirs in a clean room environment.

Intravenous fluid container, single use Australia - English - Department of Health (Therapeutic Goods Administration)

intravenous fluid container, single use

addedpharma - australia/nz - 35127 - intravenous fluid container, single use - these eva bags are a sterile single use consumables which has multiple uses; (1) it can be used as a resevoir to fill up and prepare syringes, bags and vials or (2) it can be used as a container of medication such as tpns or antibiotics which can then be connected to a medical device which is applied to the patient. please note that the eva bag does not include the tubing set which is connected to the patient, nor any medication.

General-purpose syringe/needle Australia - English - Department of Health (Therapeutic Goods Administration)

general-purpose syringe/needle

addedpharma - australia/nz - 63095 - general-purpose syringe/needle - a sterile, single-use, disposable, low-residual volume, general-purpose syringe with a 23 gauge hypodermic needle fused to the syringe. this syringe and needle combination is designed for low-dose preparation, injection, aspiration, and delivery of medication.

Syringe, general-purpose Australia - English - Department of Health (Therapeutic Goods Administration)

syringe, general-purpose

addedpharma - australia/nz - 47017 - syringe, general-purpose - a sterile, single-use syringe for general purpose, low volume preparation, injection, and aspiration of fluids from vials, ampoules, and other pharmaceutical reservoirs.

IV line/syringe Luer connector Australia - English - Department of Health (Therapeutic Goods Administration)

iv line/syringe luer connector

addedpharma - australia/nz - 60538 - iv line/syringe luer connector - self-sealing safety device for the preparation or administration of hazardous/antiblastic drugs

Syringe, general-purpose Australia - English - Department of Health (Therapeutic Goods Administration)

syringe, general-purpose

addedpharma - australia/nz - 47017 - syringe, general-purpose - in line with gmdn 47017, sterile empty syringe multipacks for general-purpose preparation, injection, and aspiration of fluids from vials, ampoules, and other pharmaceutical reservoirs in a clean room environment. it is intended for various medical applications and is not dedicated to medication administration.

RIVASTIGMINE TRANSDERMAL SYSTEM- rivastigmine patch, extended release United States - English - NLM (National Library of Medicine)

rivastigmine transdermal system- rivastigmine patch, extended release

adhexpharma - rivastigmine (unii: pki06m3iw0) (rivastigmine - unii:pki06m3iw0) - rivastigmine transdermal system is indicated for the treatment of dementia of the alzheimer's type (ad). efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer's disease. rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with parkinson's disease (pdd). rivastigmine transdermal system is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see description (11)] . - previous history of application site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis [see warnings and precautions (5.3)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the de

Imuran Tablet 50 mg Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

imuran tablet 50 mg

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - azathioprine 50 mg - 50 mg